Shares of health-care giant Johnson & Johnson (JNJ 1.41%) have climbed more than 22% since the start of 2013. Part of this Dow component's success has been its growing pharmaceutical portfolio, which includes the recently approved type 2 diabetes drug Invokana. Shares of Merck (MRK 4.96%) have also jumped around 15% year to date, but the company hasn't had a drug with blockbuster potential approved by the FDA so far this year. There is a great deal of optimism, however, surrounding Merck's PD-1 drug for the treatment of melanoma. In the following video, health-care analyst Max Macaluso discusses this experimental drug and another PD-1 drug in development at Bristol-Myers Squibb (BMY 1.33%).
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.